Cuorips

Cuorips Forward P/E

The Forward P/E Ratio of Cuorips (4894.T) as of Oct 22, 2026 is -88.33. In the previous year, Forward P/E Ratio was -140.20 — a change of -36.99% (higher).

Forward P/E

-88.33

YoY

-36.99%

Last updated:

Forward P/E Ratio of Cuorips is 2026 -88.33 . Forward P/E Ratio of Cuorips was 2025 -140.20 . It decreases by -36.99% higher compared to the previous year.

The Cuorips Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2021
-293.45 JPY
Jan 1, 2022
-240.67 JPY
Jan 1, 2023
-199.82 JPY
Jan 1, 2024
-142.89 JPY
Jan 1, 2025
-140.20 JPY
Jan 1, 2026
-88.33 JPY
The Cuorips Forward P/E history
YEARForward P/EYoY
-88.33-36.99%
-140.20-1.89%
-142.89-28.49%
-199.82-16.97%
-240.67-17.98%
-293.45—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cuorips Stock analysis

What does Cuorips do? Cuorips Inc generates revenue through regenerative medical products, primarily human iPS cell-derived cardiomyocyte sheets, and its CDMO business. The company develops these products in-house and through joint research with universities, research institutions, and major pharmaceutical companies. The CDMO services utilize CLiC-1, a commercial cell culture and processing facility with an integrated laboratory based on the Company's original design concept. Customers include major pharmaceutical companies and research institutions seeking regenerative medical solutions for the heart and other areas. The firm's regenerative medical products target heart conditions, developed through internal research and collaborations. The CDMO business provides contract development and manufacturing services using CLiC-1, serving pharmaceutical companies and research organizations. Revenue streams are derived from product sales and CDMO contracts, with the company focusing on heart-related applications and expanding into other medical areas through partnerships. Cuorips Inc's business model centers on leveraging its proprietary technology in iPS cell-derived cardiomyocyte sheets and CLiC-1 facility to serve pharmaceutical and research sectors. The company's products and services are designed for regenerative medicine applications, particularly for cardiac treatments, with sales and contracts driven by partnerships with major pharmaceutical companies and research institutions. Cuorips is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cuorips stock

Forward P/E Ratio of Cuorips is -88.33 in 2026.

Forward P/E Ratio of Cuorips changed from -140.20 to -88.33, representing a -36.99% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Cuorips since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Cuorips with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Cuorips

All Key Metrics — Cuorips